Value of CD70 in accurate diagnosis and treatment of renal cell carcinoma

doi:10.3877/cma.j.issn.1674-3253.2025.04.001

Abstract

Abstract:

Renal cell carcinoma (RCC) is one of the most common tumors of the urinary system, which is a serious threat to human health. The diagnosis and treatment of RCC are still urgent problems. As a unique biomarker of renal cell carcinoma, especially clear cell renal cell carcinoma, CD70 has a wide range of applications from diagnosis to treatment. This paper will focus on the clinical translation and application of CD70 in the diagnosis and treatment for renal cell cancer, and pay close attention to new technologies and therapies related to clinical work, as well as speculate the possible application direction in the near future.

Key words: Renal cell carcinoma, CD70, CD27, PET-CT, Immunotherapy, Targeted therapy, Biomarker

Bo Li, Wei Zhai, Junhua Zheng. Value of CD70 in accurate diagnosis and treatment of renal cell carcinoma[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(04): 399-403.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.04.001

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I04/399

References 32

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035
[2]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA A Cancer J Clinicians, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[3]	Petrau C, Cornic M, Bertrand P, et al. CD70: a potential target in breast cancer?[J]. J Cancer, 2014, 5(9): 761-764. DOI: 10.7150/jca.10360.
[4]	Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas[J]. Neuro-Oncology, 2018, 20(1): 55-65. DOI: 10.1093/neuonc/nox116.
[5]	Liu N, Sheng X, Liu Y, et al. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas[J]. Onco Targets Ther, 2013, 6: 615-619. DOI: 10.2147/OTT.S44445.
[6]	Huang RR, Chen Z, Kroeger N, et al. CD70 is consistently expressed in primary and metastatic clear cell renal cell carcinoma[J]. Clin Genitourin Cancer, 2024, 22(2): 347-353. DOI: 10.1016/j.clgc.2023.12.003.
[7]	Boursalian TE, McEarchern JA, Law CL, et al. Targeting CD70 for human therapeutic use[J]. Adv Exp Med Biol, 2009, 647: 108-119. DOI: 10.1007/978-0-387-89520-8_7.
[8]	Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block[J]. J Exp Clin Cancer Res, 2022, 41(1): 12. DOI: 10.1186/s13046-021-02215-y.
[9]	Benhamouda N, Sam I, Epaillard N, et al. Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma[J]. Clin Cancer Res, 2022, 28(22): 4983-4994. DOI: 10.1158/1078-0432.CCR-22-0905.
[10]	Ruf M, Mittmann C, Nowicka AM, et al. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27⁺ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma[J]. Clin Cancer Res, 2015, 21(4): 889-898. DOI: 10.1158/1078-0432.CCR-14-1425.
[11]	Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible[J]. CA Cancer J Clin, 2023, 73(3): 255-274. DOI: 10.3322/caac.21768.
[12]	Wei W, Younis MH, Lan X, et al. Single-domain antibody theranostics on the horizon[J]. J Nucl Med, 2022, 63(10): 1475-1479. DOI: 10.2967/jnumed.122.263907.
[13]	Krasniqi A, D'Huyvetter M, Devoogdt N, et al. Same-day imaging using small proteins: clinical experience and translational prospects in oncology[J]. J Nucl Med, 2018, 59(6): 885-891. DOI: 10.2967/jnumed.117.199901.
[14]	Cleeren F, Lecina J, Bridoux J, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method[J]. Nat Protoc, 2018, 13(10): 2330-2347. DOI: 10.1038/s41596-018-0040-7.
[15]	Qin X, Guo X, Liu T, et al. High in-vivo stability in preclinical and first-in-human experiments with [¹⁸F] AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2): 302-313. DOI: 10.1007/s00259-022-05967-7.
[16]	Wang C, Chen Y, Hou YN, et al. ImmunoPET imaging of multiple myeloma with [⁶⁸Ga] Ga-NOTA-Nb1053[J]. Eur J Nucl Med Mol Imag, 2021, 48(9): 2749-2760. DOI: 10.1007/s00259-021-05218-1.
[17]	Wu Q, Wu Y, Zhang Y, et al. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F] RCCB6: a first-in-human study[J]. Eur J Nucl Med Mol Imag, 2024, 51(8): 2444-2457. DOI: 10.1007/s00259-024-06672-3.
[18]	Gelardi F, Larcher A, Antunovic L, et al. Biological characterization of renal masses using immuno-PET[J]. Eur J Nucl Med Mol Imaging, 2024, 51(8): 2442-2443. DOI: 10.1007/s00259-024-06757-z.
[19]	Wu Q, Wu Y, Zhang Y, et al. [¹⁸F] RCCB6 immuno-positron emission tomography/computed tomography for postoperative surveillance in clear cell renal cell carcinoma: a pilot clinical study[J]. Eur Urol, 2024, 86(4): 372-374. DOI: 10.1016/j.eururo.2024.06.020.
[20]	Riether C, Pabst T, Höpner S, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents[J]. Nat Med, 2020, 26(9): 1459-1467. DOI: 10.1038/s41591-020-0910-8.
[21]	Tannir NM, Forero-Torres A, Ramchandren R, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma[J]. Invest New Drugs, 2014, 32(6): 1246-1257. DOI: 10.1007/s10637-014-0151-0.
[22]	Pal SK, Forero-Torres A, Thompson JA, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma[J]. Cancer, 2019, 125(7): 1124-1132. DOI: 10.1002/cncr.31912.
[23]	Li S, Chen D, Guo H, et al. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling[J]. Front Oncol, 2023, 13: 1240061. DOI: 10.3389/fonc.2023.1240061.
[24]	Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors[J]. Theranostics, 2020, 10(17): 7622-7634. DOI: 10.7150/thno.43991.
[25]	Xiong Q, Wang H, Shen Q, et al. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment[J]. J Transl Med, 2024, 22(1): 368. DOI: 10.1186/s12967-024-05101-1.
[26]	Ji F, Zhang F, Zhang M, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway[J]. J Hematol Oncol, 2021, 14(1): 152. DOI: 10.1186/s13045-021-01168-1.
[27]	Panowski SH, Srinivasan S, Tan N, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma[J]. Cancer Res, 2022, 82(14): 2610-2624. DOI: 10.1158/0008-5472.CAN-21-2931.
[28]	Pal SK, Tran B, Haanen JBAG, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma[J]. Cancer Discov, 2024, 14(7): 1176-1189. DOI: 10.1158/2159-8290.CD-24-0102.
[29]	Nagato T, Komatsuda H, Hayashi R, et al. Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma[J]. Cancer Sci, 2024, 115(4): 1073-1084. DOI: 10.1111/cas.16079.
[30]	Świderska J, Kozłowski M, Gaur M, et al. Clinical significance of BTLA, CD27, CD70, CD28 and CD80 as diagnostic and prognostic markers in ovarian cancer[J]. Diagnostics (Basel), 2022, 12(2): 251. DOI: 10.3390/diagnostics12020251.
[31]	Massard C, Soria JC, Krauss J, et al. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2019, 83(6): 1057-1063. DOI: 10.1007/s00280-019-03796-4.
[32]	Aftimos P, Rolfo C, Rottey S, et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies[J]. Clin Cancer Res, 2017, 23(21): 6411-6420. DOI: 10.1158/1078-0432.CCR-17-0613.

Please choose a citation manager

Content to export